Entry into a Material Definitive Agreement. On August 19, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), entered into an Assignment and Transfer Agreement of Certain Apitox Rights (the “ Assignment Agreement ”) with FreeT Inc., a company organized under the laws of the Republic of Korea (“ FreeT ”). FreeT is the successor to CNP Roen Co., Ltd., which subsequently changed its corporate name to Inscobee Co., Ltd. and is currently known as FreeT Inc. Pursuant t…

Co-Chief Executive Officer — Sungjoon Chae: Sungjoon Chae was appointed as Co-Chief Executive Officer of the Company.

Entry into a Material Definitive Agreement. On April 24, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), MindWave Innovations Inc, a Delaware corporation and a wholly owned subsidiary of the Company (“ MindWave ”), and Lokahi Therapeutics, Inc., a Nevada corporation (“ Lokahi ” and, together with the Company and MindWave, the “ Company Parties ”), together with Erik Emerson (“ Emerson ”), individually and in his capacity as Bio Business Representative under t…

Director — Jakap Koo: Mr. Koo's resignation or removal is part of a significant corporate settlement and restructuring.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On April 17, 2026, Apimeds Pharmaceuticals US, Inc. (the “ Company ”) received a notice from the NYSE Regulation staff of the New York Stock Exchange (“ NYSE ”) indicating that the Company is not in compliance with NYSE’s continued listing requirements under the timely filing criteria outlined in Section 1007 of the NYSE American Listed Company Manual as a result of the Company’s failure to t…

multiple roles including CEO, CFO, Directors — Elona Kogan, Jakap Koo, Carol O’Donnell, Dr. Bennett Weintraub, Dr. Vin Menon, Erick Frim: The removal of multiple directors and officers was in violation of the Support Agreement and Delaware law.

The stockholder consent claiming to remove directors and officers is invalid and does not result in any actual departures.

Director/CEO — Elona Kogan, Jakap Koo, Carol O’Donnell, Dr. Bennett Weintraub, Dr. Vin Menon: Directors and the CEO were removed due to concerns over potential wrongdoing related to a merger transaction.

Other Events. Business Expansion On March 20, 2026, the Board approved the expansion of the Company’s business into new business initiatives and operations, including pursuing strategic opportunities such as joint ventures with other Korean companies to expand the current business of the Company into Korean cosmetics, photo booth platform business and e-commerce markets (the “Business Expansion”). In connection therewith, the Boad approved the Company’s entry into non-binding memoranda of und…

Completion of Acquisition or Disposition of Assets. The disclosure set forth under

Director — Erik Emerson: Erik Emerson was removed from the board of directors by stockholders.

Director — Dr. Vin Menon and Amir A. Dossal: Two directors resigned from their positions on the Board of Directors.

Entry Into a Material Definitive Agreement. Merger Agreement As previously disclosed, on December 1, 2025, Apimeds Pharmaceuticals US, Inc, a Delaware corporation (the “ Acquiror ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with (i) Apimeds Merger Sub, Inc., a Delaware corporation, (ii) MindWave Innovations Inc, a Delaware corporation (the “ Company ”), (iii) Lokahi Therapeutics, Inc., a Nevada corporation, and (iv) Erik Emerson, solely in his capacity as repres…

Material Modification to Rights of Security Holders. The information set forth in

Changes in Control of Registrant. The disclosure set forth above in

Entry Into A Material Definitive Agreement. Merger Agreement This section describes the material provisions of the Merger Agreement (as defined herein) but does not purport to describe all of the terms thereof. Apimeds Pharmaceuticals US, Inc.’s stockholders and other interested parties are urged to read such agreement in its entirety. The following summary is qualified in its entirety by reference to the complete text of the Merger Agreement, a copy of which is attached hereto as Exhibit 2.1…

The excerpt provides biographical information about Dr. Vin Menon and does not describe a management change event.

Completion of Acquisition or Disposition of Assets. The disclosure set forth above in

by reference. The issuance of the Merger Consideration and the offer, sale and issuance of the Notes have not been registered under the Securities Act of 1933, as amended (the “ Securities Act ”), in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act. On December 1, 2025, the Acquiror issued a warrant to E.F. Hutton & Co. LLC, to purchase 712,880 shares of Acquiror Common Stock, at an exercise price of per share (the “ E.F. Hutton Warrant ”). The E…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth above in

Chief Executive Officer — Erik Emerson: The amendment to the employment agreement includes a salary increase and updated severance terms.

Chief Financial Officer — Erick J. Frim: Appointment of Erick J. Frim as Chief Financial Officer, replacing Mark Corrao.

Entry into a Material Definitive Agreement. On May 16, 2025, Apimeds Pharmaceuticals US, Inc. (the “Company”) amended the terms of three outstanding promissory notes as further described below. On May 20, 2024, the Company issued to Inscobee Inc. (“Inscobee”) a promissory note in the principal amount of $100,000 (the “May 2024 Note”). On August 19, 2024, the Company issued to Inscobee a promissory note in the principal amount of $150,000 (the “August 2024 Note”). On March 31, 2025, the Compan…

Entry into a Material Definitive Agreement. On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (the “Company”) consummated its initial public offering (the “IPO”) of 3,375,000 shares of common stock, par value $0.01 per share (“Common Stock”), at a price of $4.00 per share, generating gross proceeds to the Company of $13.5 million before deducting underwriting discounts and offering expenses. The Company’s Registration Statement on Form S-1 (File No. 333-282324) for the IPO (the “Registration…

Unregistered Sales of Equity Securities. In connection with the closing of the IPO, three convertible promissory notes (as amended, the “Notes”) automatically converted into shares of Common Stock. Pursuant to the terms of the Notes, all outstanding accrued and unpaid interest owed under the Notes was to convert into Common Stock simultaneously with the consummation of an offering of Common Stock resulting in the listing of the Common Stock on the NYSE American, or other national securities e…